News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
749,303 Results
Type
Article (45626)
Company Profile (339)
Press Release (703320)
Multimedia
Podcasts (141)
Webinars (21)
Section
Business (212945)
Career Advice (2200)
Deals (37248)
Drug Delivery (132)
Drug Development (84618)
Employer Resources (178)
FDA (16979)
Job Trends (15676)
News (361353)
Policy (34651)
Tag
2027 Biotech Bay Standard (2)
2027 Genetown Elite (2)
2027 Pharm Country Elite (1)
2027 Pharm Country Standard (3)
Academia (2644)
Accelerated approval (32)
Adcomms (33)
Allergies (145)
Alliances (52226)
ALS (175)
Alzheimer's disease (1703)
Antibody-drug conjugate (ADC) (335)
Approvals (17216)
Artificial intelligence (538)
Autoimmune disease (152)
Automation (37)
Bankruptcy (378)
Best Places to Work (11842)
BIOSECURE Act (22)
Biosimilars (200)
Biotechnology (195)
Bladder cancer (158)
Brain cancer (59)
Breast cancer (648)
Cancer (4902)
Cardiovascular disease (428)
Career advice (1854)
Career pathing (39)
CAR-T (287)
CDC (50)
Celiac Disease (2)
Cell therapy (763)
Cervical cancer (36)
Clinical research (72062)
Collaboration (1767)
Company closure (5)
Compensation (1164)
Complete response letters (66)
COVID-19 (2807)
CRISPR (95)
C-suite (847)
Cystic fibrosis (149)
Data (6221)
Decentralized trials (2)
Denatured (41)
Depression (138)
Diabetes (516)
Diagnostics (6788)
Digital health (44)
Diversity (13)
Diversity, equity & inclusion (46)
Drug discovery (256)
Drug pricing (218)
Drug shortages (34)
Duchenne muscular dystrophy (232)
Earnings (92238)
Editorial (60)
Employer branding (21)
Employer resources (157)
Events (121397)
Executive appointments (994)
FDA (20108)
Fibrodysplasia Ossificans Progressiva (6)
Friedreich's ataxia (10)
Frontotemporal dementia (23)
Funding (1484)
Gene editing (205)
Generative AI (48)
Gene therapy (619)
GLP-1 (1075)
Government (4879)
Grass and pollen (7)
Guidances (385)
Healthcare (19203)
HIV (57)
Huntington's disease (45)
IgA nephropathy (85)
Immunology and inflammation (275)
Immuno-oncology (58)
Indications (104)
Infectious disease (3079)
Inflammatory bowel disease (194)
Inflation Reduction Act (14)
Influenza (110)
Intellectual property (247)
Interviews (344)
IPO (17086)
IRA (57)
Job creations (4175)
Job search strategy (1560)
JPM (68)
Kidney cancer (16)
Labor market (84)
Layoffs (601)
Leadership (37)
Legal (8577)
Liver cancer (93)
Longevity (15)
Lung cancer (659)
Lymphoma (377)
Machine learning (43)
Management (62)
Manufacturing (819)
MASH (171)
Medical device (13890)
Medtech (13942)
Mergers & acquisitions (21233)
Metabolic disorders (1360)
Multiple sclerosis (162)
NASH (20)
Neurodegenerative disease (330)
Neuropsychiatric disorders (95)
Neuroscience (2968)
Neurotech (1)
NextGen: Class of 2026 (6734)
Non-profit (4584)
Now hiring (65)
Obesity (663)
Opinion (305)
Ovarian cancer (166)
Pain (215)
Pancreatic cancer (225)
Parkinson's disease (291)
Partnered (34)
Patents (500)
Patient recruitment (480)
Peanut (59)
People (61385)
Pharmaceutical (100)
Pharmacy benefit managers (33)
Phase 1 (22482)
Phase 2 (31630)
Phase 3 (23695)
Pipeline (5151)
Policy (310)
Postmarket research (2687)
Preclinical (9480)
Press Release (68)
Prostate cancer (240)
Psychedelics (49)
Radiopharmaceuticals (287)
Rare diseases (871)
Real estate (6414)
Recruiting (71)
Regulatory (25693)
Reports (51)
Research institute (2457)
Resumes & cover letters (372)
Rett syndrome (27)
RNA editing (18)
RSV (83)
Schizophrenia (155)
Series A (246)
Series B (190)
Service/supplier (14)
Sickle cell disease (99)
Special edition (26)
Spinal muscular atrophy (163)
Sponsored (42)
Startups (3833)
State (2)
Stomach cancer (19)
Supply chain (111)
Tariffs (100)
The Weekly (98)
Vaccines (1038)
Venture capital (92)
Weight loss (454)
Women's health (88)
Worklife (19)
Date
Last 7 days (616)
Last 30 days (2068)
Last 365 days (30623)
2026 (2909)
2025 (31088)
2024 (36146)
2023 (40929)
2022 (52114)
2021 (56674)
2020 (55108)
2019 (47821)
2018 (36140)
2017 (33570)
2016 (33169)
2015 (39008)
2014 (32960)
2013 (28077)
2012 (30165)
2011 (30871)
2010 (28889)
Location
Africa (828)
Alabama (84)
Alaska (7)
Arizona (314)
Arkansas (14)
Asia (43124)
Australia (6847)
California (11267)
Canada (3285)
China (1144)
Colorado (477)
Connecticut (473)
Delaware (338)
Europe (92814)
Florida (1691)
Georgia (354)
Hawaii (3)
Idaho (61)
Illinois (873)
India (65)
Indiana (529)
Iowa (22)
Japan (432)
Kansas (125)
Kentucky (38)
Louisiana (26)
Maine (72)
Maryland (1392)
Massachusetts (8116)
Michigan (323)
Minnesota (628)
Mississippi (5)
Missouri (125)
Montana (31)
Nebraska (28)
Nevada (125)
New Hampshire (78)
New Jersey (3012)
New Mexico (31)
New York (2972)
North Carolina (1502)
North Dakota (8)
Northern California (5474)
Ohio (334)
Oklahoma (22)
Oregon (47)
Pennsylvania (2278)
Puerto Rico (23)
Rhode Island (47)
South America (1196)
South Carolina (66)
South Dakota (1)
Southern California (4380)
Tennessee (174)
Texas (1746)
United States (40153)
Utah (338)
Vermont (1)
Virginia (274)
Washington D.C. (82)
Washington State (925)
West Virginia (4)
Wisconsin (112)
Wyoming (2)
749,303 Results for "hookipa pharma inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
HOOKIPA Pharma Announces Sale of Oncology Assets to NeoTrail Therapeutics
February 3, 2026
·
3 min read
Pharm Country
HOOKIPA Pharma to Participate in Leerink Partners Global Biopharma Conference
HOOKIPA Pharma Inc. announced that HOOKIPA’s Chief Financial Officer, Reinhard Kandera, will present at the Leerink Partners Global Biopharma Conference on March 13, 2024.
March 6, 2024
·
3 min read
Pharm Country
HOOKIPA Pharma to Host Investor Call on HB-200 Data Presented at American Society of Clinical Oncology 2024 Annual Meeting
HOOKIPA Pharma Inc. today announced that members of HOOKIPA’s Executive Team will host an investor call on June 4, 2024, at 4:15 p.m. ET.
May 30, 2024
·
5 min read
Pharm Country
HOOKIPA Pharma to Host Investor Call on HB-200 and Planned Path to Registration
HOOKIPA Pharma Inc. announced that members of HOOKIPA’s Executive Team will host an investor call summarizing the Company’s constructive regulatory interactions with the U.S. Food & Drug Administration and the European Medicines Agency.
April 10, 2024
·
5 min read
Business
HOOKIPA Pharma Reports First Quarter 2024 Financial Results and Recent Business Highlights
HOOKIPA Pharma Inc., a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, reported financial results and recent business highlights for the first quarter of 2024.
May 9, 2024
·
11 min read
Japan
Japanese Pharmas Looking Beyond Borders for M&A to US, EU
Long a quieter, locally focused industry, Japanese pharma giants are increasingly looking to the rest of the world for deals.
December 10, 2025
·
7 min read
·
Dan Samorodnitsky
Pharm Country
HOOKIPA Pharma Announces Positive Clinical Data to be Presented at the American Society for Clinical Oncology 2024 Annual Meeting
HOOKIPA Pharma Inc. announced positive updated results from its Phase 1/2 clinical trial of HB-200 for the treatment of human papillomavirus 16 positive head and neck cancers.
May 23, 2024
·
11 min read
Press Releases
As mental health patients turn to AI chatbots, how can pharma lead the way?
A new report by Bryter released today reveals where pharma can lead as patients turn to (and question) AI tools for mental health.
February 5, 2026
·
1 min read
Business
HOOKIPA Pharma Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Highlights
HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, today reported financial results and business highlights for the fourth quarter and full year 2023.
March 22, 2024
·
15 min read
Drug Development
HOOKIPA Pharma Announces Updated Phase 2 Clinical Data at the American Society of Clinical Oncology 2024 Annual Meeting
HOOKIPA Pharma Inc. today announced positive updated results from its Phase 2 clinical trial of HB-200 in combination with pembrolizumab in patients with recurrent/metastatic human papillomavirus 16 positive (HPV16+) head and neck cancer.
June 4, 2024
·
10 min read
1 of 74,931
Next
